Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study

Type 2 diabetes (T2D) is a complex disease for which an individualised treatment approach is recommended. Once-weekly (OW) semaglutide is a glucagon-like peptide-1 receptor agonist approved for the treatment of insufficiently controlled T2D. The aim of this study was to investigate the use of OW sem...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellido, Virginia, Abreu Padín, Cristina, Catarig, Andrei-Mircea, Clark, Alice, Barreto Pittol, Sofía, Delgado, Elias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456474/
https://www.ncbi.nlm.nih.gov/pubmed/36078869
http://dx.doi.org/10.3390/jcm11174938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456474/
https://www.ncbi.nlm.nih.gov/pubmed/36078869
http://dx.doi.org/10.3390/jcm11174938

Ejemplares similares